Here're the slides presented in November 2023:
The PMS phase 3 asset will potentially be the next big company maker.
NEU's the most advanced trial on PMS.
PMS' market size is around Three times of Rett Sydrome (DAYBUE).
DAYBUE's similar rare disease drug SKYCLARYS which was acquired for US$7.3B.
That's the reason of why NEU is going alone with the phase 3 trial, as we wanna own 100%, then fully realise its potential.
Next catalyst will be type c meeting with FDA in early April, so around five weeks away.
all imo.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.85 |
Change
-0.110(0.85%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.53 | $6.559M | 511.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1657 | $12.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.85 | 6303 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |